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ABSTRACT 
 
Background: The cytokines genes polymorphisms are important determinants for the outcome of HCV infection 
and degree of liver fibrosis and inflammation. Recently, it has been revealed that hepatocytes and hepatic 
macrophages produce mature IL-1β through the NLRP3 (NOD-like receptor, pyrin domain containing 3) 
inflammasome assembly which represents a link between hepatitis C virus infection and liver inflammation. In 
addition, NLRP3 inflammasome has emerged as a cytoplasmic sensor of HCV participating in eliciting the innate 
immune response against HCV. 
Objective: To explore the association of a genetic variation within 3’UTR NLRP3 gene with the degree of liver 
fibrosis and /or liver inflammation. Moreover, to investigate possible relation between fibrosis and the HCV load 
quantified at the diagnosis of Egyptian HCV patients. 
Methods: We studied the distribution of genotypes and alleles of one NLRP3 SNP (rs10754558) in one hundred-
forty seven chronic HCV patients using Taq Man predesigned SNP genotyping assay.  
Results: The genotype distribution and allele frequencies of NLRP3 (rs10754558) polymorphism did not differ 
significantly neither with the degree of liver fibrosis nor with the degree of liver inflammation or the baseline HCV 
quantity.  
Conclusions: NLRP3 (rs10754558) polymorphism was not associated neither with the degree of liver fibrosis nor 
with the degree of liver inflammation and amplitude of baseline HCV load measured during diagnosis of Egyptian 
patients chronically infected with HCV genotype 4a. Importantly, the pivotal role played by the NLRP3 in the 
immune response against HCV infection requires further studies for other polymorphisms within NLRP3 gene to 
unravel their role in HCV infection. 
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Introduction 
 
 
Hepatitis C virus (HCV) represents one of the global 
public health problems. Its prevalence has expanded 
intensely over the last 15 years to reach more than 185 
million infections worldwide [1]. Egypt has the highest 
HCV prevalence worldwide, with an predictable 
overall prevalence of 21.9% between adults [2].The 
major burden from HCV infection comes from 
sequelae from chronic infection [3]. About 75% of the 
infected patients become chronically infected and at 
risk of developing cirrhosis and liver cancer [3]. An  
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important factor in the pathogenesis of chronic HCV  
disease is liver damage sustained by the development 
of inflammation and tissue fibrosis. Scoring of these 
two criteria is used as a measure of disease state and 
progression [4-5].The prognosis of  HCV infection is 
the result of complex interaction between viral 
virulence factors and host’s response mechanism which 
may vary from spontaneous recovery to asymptomatic 
patient, and may progress to liver fibrosis. Stimulation 
and release of proinflammatory cytokines, IL-1β and 
IL-18, is an essential step for the activation of an 
effective innate host defense, and subsequently for the 
modulation of adaptive immune responses [7]. 
Notably; these cytokines have found to play a dual role 
in HCV viral infection. In acute infection, these 
cytokines have an antiviral effect assisting in viral 
clearance. Besides, IL-1β has been shown to hinder 
replication of HCV. This means that they may 
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influence the baseline viral load of HCV[8-10].On the 
other hand, IL-1β is a master cytokine in inflammation 
and it regulates diverse cellular processes in chronic 
HCV infection. It induces potent inflammatory 
molecules such as cox-2, nitric oxide and TNF-α [11]. 
The persistent induction of IL-1β by hepatic 
macrophages in chronic hepatitis C patients would then 
help to recruit immune cells to the liver causing liver 
inflammation. Most importantly, persistent liver 
inflammation during HCV infection is thought to serve 
as a platform for progressive liver injury,liver cirrhosis 
and liver cancer[12-13]. Interleukin-1β is synthesized 
as an inactive precursor that is processed into the 
biologically active form through recruitment of the 
inflammasome. The inflammasome is multi-protein 
complex consisting mainly of a Nod like receptor 
(NLR), adaptor molecule (ASC) and procaspase-1. 
Upon assembly of the inflammasome, caspase-1 is 
activated which in turn cleaves pro-IL-1β and pro-IL-
18 into their mature form [14]. Numerous studies have 
provided evidences on the role of NLRP3 and ASC in 
inflammatory processes associated with chronic 
HCV[15-16]. Recently, it has been revealed that 
hepatocytes and hepatic macrophages produce mature 
IL-1β through the NLRP3 inflammasome assembly 
which represents a link between hepatitis C virus 
infection and liver inflammation [15][16].In addition, 
the genetic factors influence progression of fibrosis. 
Several genetic polymorphisms were found to be 
associated with progression of fibrosis [17].  
Transforming growth factor-b1 [18], complement 
factor-5 [19], angiotensinogen [20], monocyte 
chemotactic protein-1 [21] and microsomal epoxide 
hydrolase genes [22] and Toll-like receptor 7 [23] are 
among the genes which have polymorphisms that were 
associated with the fibrosis degrees. Although, several 
single nucleotide polymorphisms (SNPs) in the pro-
inflammatory cytokines have been extensively studied, 
the effect of the polymorphisms in the inflammasome 
genes on HCV outcome is unexplored yet. Thus the 
objective of the current study was to investigate the 
role of a genetic variation within NLRP3 gene 
(rs10754558) in the degree of liver fibrosis and 
inflammation Egyptian patients chronically infected 
with HCV. Besides, determination of its role in the 
extent of the baseline viral load quantified on diagnosis 
of HCV patients. 
 
Patients and methods 
 
Patients 
This study included 147 chronically HCV infected 
patients recruited from the National Hepatology and 
Tropical Medicine Research Institute (NHTMRI), 
Cairo, Egypt.  
The study has been conducted in accordance with 
national protocols for the treatment of chronic hepatitis 
C approved by Institutional Review Board (IRB) for 
Human Subject Research. This national protocol has 
been issued by the National Committee for Control of 
Viral Hepatitis, Ministry of Health in Egypt. This 
committee is organized and operated according to the 
Declaration of Helsinki for human subjects (2008). 
Moreover, an informed consent was obtained from 
every  participant. 
The selection criteria for chronic HCV patients were 
positive for HCV Ab and positive viremia at the time 
of diagnosis. The exclusion criteria were viral 
infections, bilharziasis, and any other autoimmune 
diseases or cancers.  
A complete medical history and biochemical 
parameters were obtained from the patients’ files. 
Moreover, the METAVIR score which was evaluated 
in the liver biopsy for all patients before starting the 
treatment was also obtained from the patient’s records. 
This score helps to determine the degree of liver 
inflammation and fibrosis. It is a semi quantitative 
scoring system described by Scheuer [24]. The degree 
of inflammation was graded on a scale of 0–4 (0: 
absent; 1: minimal; 2: mild; 3: moderate; 4: severe). 
The degree of fibrosis was staged on a scale of 0–4 (0: 
absent; 1: mild without septa; 2: moderate with few 
septa; 3: numerous septa without cirrhosis; 4: 
cirrhosis).  
 
Blood sample and DNA isolation 
 
A peripheral venous blood sample of 2 ml was drawn 
from each individual. The blood sample was collected 
in sterile anticoagulant tubes. Genomic DNA was 
extracted from EDTA whole blood using Pure Link® 
Genomic DNA Mini Kit; Invitrogen, USA. 
 
Genetic polymorphism detection 
 
One SNP (rs10754558) within NLRP3 gene was 
genotyped in this study. The genotyping was 
performed using TaqMan Predesigned SNP 
Genotyping Assay; Invitrogen, Applied Biosystem, 
USA and TaqMan Universal Master Mix II, no UNG; 
Invitrogen, USA.  
The PCR for detection of SNP was carried out 
according to the manufacturer’s instructions using 
Rotor-Gene® Qiagen, real time PCR, USA. Allelic 
discrimination was performed using Rotor –Gene Q 
Software version: 2.0.2 (Build 4). 
 
 
Asian Pac. J. Health Sci., 2015; 2(3): 116-122                                          e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Estfanous et al     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2015; 2(3): 116-122 
www.apjhs.com      118 
 
Statistical analysis 
 
Statistical analyses were conducted by software 
package SPSS version 21 (SPSS, Chicago, IL, USA). 
Continuous variables of demographic and 
anthropometric characteristics were compared by the 
use of Student’s t test while for more than 2 groups 
ANOVA test was computed. The genotype and allele 
frequencies were calculated using gene-counting 
method. Univariate comparisons of categorical 
variables were performed with Chi–square test. Allele 
frequencies and genotype distributions between the 
studied groups were compared by chi square test and 
Fisher’s exact test when expected value < 5 were found 
for any cell. The nominal level of statistical 
significance for all analyses was p < 0.05. 
 
Results 
 
Patients’ characteristics are listed in table 1. The 
genotype distributions of the HCV patients were in 
Hardy–Weinberg equilibrium. The assessment of the 
impact of genotype and allele frequencies of NLRP3 
C-29940G polymorphism on the degree of liver 
fibrosis and liver inflammation are shown in table 2 
and 3 respectively. Moreover, the relation between the 
degree of liver fibrosis and the baseline viral load is 
shown in table 4. No significant difference in genotype 
distribution or allele frequencies was found neither in 
the degrees of liver fibrosis nor in degrees of liver 
inflammation. In addition , no significant effect was 
manifested between the serum viral load and the degree 
of liver fibrosis 
 
Table 1: Patients’ characteristics 
 
Sex Male 94 (63.9%) 
Female 53 (36.1%) 
Age  41 ± 10 
BMI 27 ± 4 
ALT 57±28 
AST 48±24 
αFP 9.5±17.5 
 
Degree of Fibrosis                          
F1 89 (60.5%) 
F2 30 (20.4%) 
F3 28 (19%) 
 
Degree of Inflammation 
A0 1 (0.7 %) 
A1 105 (71.4 %) 
A2 32 (21.8 %) 
A3 5 (3.4 %) 
A4 4 (2.7 %) 
 
BMI= Body mass index, ALT= alanine transaminase, AST= aspartate transaminase, αFP= alpha-feto protein, 
quantative data expressed as mean ± S.D. 
 
Table 2: Impact of allele and genotype frequencies of NLRP3 gene C-29940G (rs10754558) polymorphism on 
the degree of liver fibrosis. 
 F1 
(N=89) 
F2 
(N=30) 
F3 
(N=28) 
P-value 
CC 17(19.1%) 5 (16.7%) 8(28.6%) 0.47 
CG 47(52.8%) 16(53.3%) 15(53.6%) 0.99 
GG 25(28.1%) 9(30%) 5(17.9) 0.5 
C 81(45.5%) 26(43.3%) 31(55.4%) 0.36 
G 97(54.5%) 34(56.7%) 25(44.6%) 0.36 
 
The statistical analyses were conducted using Chi-square test 
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Table 3: Impact of allele and genotype frequencies of NLRP3 gene C-29940G (rs10754558) polymorphism 
impact on the degree of liver inflammation. 
 A0-A1 
(N=106) 
A2 
(N=32) 
A3-A4 
(N=9) 
P-value 
CC 21(19.8%) 7(21.9%) 2(22.2%) 0.96 
CG 55(51.9%) 19(59.4%) 4(44.4%) 0.66 
GG 30(28.3%) 6(18.6%) 3(33.3%) 0.5 
C 97(45.8%) 33(51.6%) 8(44.4%) 0.7 
G 115(54.2%) 31(48.4%) 10(55.6%) 0.7 
 
The statistical analyses were conducted using Chi-square test 
 
Table 4: Relation between the degree of liver inflammation and the extent of the initial viral load 
 
Metavir 
(degree of fibrosis) 
Log (Viral Load) ANOVA result 
Mean S.E. of Mean P-value 
F1 5.49 0.1 0.467 
F2 5.7 0.15 
F3 5.4 0.15 
 
The statistical analyses were conducted using ANOVA test 
 
Discussion 
 
Hepatic inflammation during chronic HCV infection is 
the key player in progression of liver disease and 
consequently development of liver cancer [12]. 
Inflammasome are molecular platforms known to be 
involved in recognizing pathogens and eliciting the 
innate immune response [14]. Notably, IL-1β and the 
NLRP3 inflammasome has been found to be essential 
factors for dendritic cell maturation, antigen 
presentation and T cell activation[25-27]. This is 
supporting the notion that NLRP3 inflammasome 
modulates the acquired immunity as well as the innate 
immunity against several pathogens. Recently, 
numerous studies have demonstrated that NLRP3 
inflammasome is a cytoplasmic sensor of HCV which 
upon activation recruits several proteins in multiprotein 
complex resulting in the activation of caspase-1 and 
maturation of IL-1β. Interestingly this role of NLRP3 
in innate immune response against HCV have been 
reported in different types of cells including monocytes  
 
hepatocytes and liver macrophages [15-16,28].. 
Moreover, it has been discovered that IL-1β production 
through the NLRP3 inflammasome by hepatic 
macrophages links hepatitis C virus infection with liver 
inflammation and disease [15]. Thus the objective of 
the current study was to investigate the role of a 
genetic variation within NLRP3 gene (rs10754558) in 
the degree of liver fibrosis and inflammation Egyptian 
patients chronically infected with HCV. The studied 
single nucleotide polymorphism (rs10754558) was 
selected based on the previously published literatures 
showing that the G allele of this 3’UTR SNP enhances 
mRNA stability [29] that secures more active NLRP3 
protein[30-31]. NLRP3 (rs10754558) polymorphism 
was not associated neither with degree of liver fibrosis 
nor with the degree of liver inflammation. Because the 
allele and genotype frequency distribution of NLRP3 
(rs10754558) were similar within different groups of 
liver fibrosis and inflammation.  Moreover, the allelic 
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distribution of NLRP3 (rs10754558) did not vary 
significantly with the initial viral load quantified at the 
diagnosis. Notably, the current study has been 
conducted on the Egyptian patients with HCV 
genotype 4a. So the findings of our study does not 
exclude associations between genetic variation in 
NLRP3 (rs10754558) and the degree of fibrosis and 
inflammation in other populations with different HCV 
genotypes.  
Conclusion 
The selected 3’UTR SNP (rs10754558) in NLRP3 gene 
is affecting the mRNA stability and consequently the 
intracellular NLRP3 protein level. Yet, we could not 
find any significant association for this SNP with the 
degree of liver fibrosis and inflammation in Egyptian 
HCV patients. Nevertheless, the crucial role played by 
the NLRP3 inflammasome in the immune response 
against HCV infection necessitates further 
investigations for other polymorphisms within NLRP3 
gene to unveil their role of in HCV infection and 
disease outcome in the chronic HCV patients. 
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